| Study | Reason for exclusion |
|---|---|
| Akizawa 2015a | Wrong intervention/control: different dosing regimens of JTZ‐951 |
| Akizawa 2019a | Duration of follow‐up < 8 weeks Phase 1: patients randomised to different doses of enarodustat versus placebo for 6 weeks Phase 2: all participants, including those in the placebo group, took enarodustat until the end of the follow‐up period. It was not clearly stated if the second phase was randomised |
| Akizawa 2019b | Duration of follow‐up < 8 weeks Phase 1: patients randomised to different doses of enarodustat versus placebo for 6 weeks Phase 2: all participants, including those in the placebo group, took enarodustat until the end of the follow‐up period. It was not clearly stated if the second phase was randomised |
| Akizawa 2020 | Wrong intervention: patients not previously receiving ESA were randomised to roxadustat at a starting dose of 50 or 70 mg 3 times/week; patients previously receiving ESA switched from ESA to roxadustat 70 or 100 mg 3 times/week depending on the prior ESA dose |
| Akizawa 2020b | Wrong intervention/control: different dosing regimens of roxadustat |
| Akizawa 2020g | Wrong intervention: patients not previously receiving ESA were randomised to roxadustat at a starting dose of 50 or 70 mg 3 times weekly; patients previously receiving ESA switched from ESA to roxadustat 70 or 100 mg three times weekly depending on the prior ESA dose |
| ASCEND:Fe 2018 | Duration of follow‐up < 8 weeks: protocol reporting that at day 28 participants will be crossed over |
| ASCEND‐BP 2017 | Duration of follow‐up < 8 weeks: protocol reporting that at day 28 participants will be crossed over |
| Bailey 2019 | Duration of follow‐up < 8 weeks |
| Besarab 2016 | Wrong intervention/control: roxadustat + no iron, roxadustat + oral iron, roxadustat + IV iron |
| Buch 2014 | Duration of follow‐up < 8 weeks |
| DD‐CKD 2020 | Duration of follow‐up < 8 weeks: 2 RCTs were included, with dialysis or CKD participants. In both studies in the first 6 weeks patients were randomised to vadadustat 150, 300 or 600 mg versus placebo. For the following 10 weeks vadadustat dose adjustments to achieve target Hb level of 10.0 to 12.0 g/dL, and placebo patients switched to vadadustat 150, 300 or 600 mg. It was not clearly stated if the second phase was randomised for a second time |
| EudraCT2012‐004049‐34 | Duration of follow‐up < 8 weeks |
| EudraCT2012‐004050‐29 | Duration of follow‐up < 8 weeks |
| EudraCT2015‐004790‐32 | Duration of follow‐up < 8 weeks |
| Frohna 2007 | Duration of follow‐up < 8 weeks |
| Haase 2016 | Wrong intervention/control: different dosing regimens of vadadustat |
| Hartman 2014 | Duration of follow‐up < 8 weeks |
| Holdstock CKD 2016 | Duration of follow‐up < 8 weeks |
| Holdstock HD 2016 | Duration of follow‐up < 8 weeks |
| Martin 2017 | Duration of follow‐up < 8 weeks |
| NCT01679587 | Wrong intervention/control: different dosing regimens of molidustat |
| NCT01971164 | Duration of follow‐up < 8 weeks |
| NCT03992066 | Duration of follow‐up < 8 weeks |
| NCT04059913 | Wrong intervention/control: different dosing regimens of roxadustat |
| Pai 2015 | Duration of follow‐up < 8 weeks |
| Parmar 2019 | Duration of follow‐up < 8 weeks |
| Provenzano 2011 | Duration of follow‐up < 8 weeks |
| Provenzano 2011a | Duration of follow‐up < 8 weeks |
| Provenzano 2016b | Wrong intervention/control: different dosing regimens of roxadustat |
| Wiecek 2005 | Duration of follow‐up < 8 weeks |
CKD ‐ chronic kidney disease; ESA ‐ erythropoietin‐stimulating agent; Hb ‐ haemoglobin; IV ‐ intravenous; RCT ‐ randomised controlled trial